Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C24H19ClN4O4 |
| Molecular Weight | 462.885 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)NC1=NC2=C(N1)C=CC(=C2)C3(O)N(C(=O)C4=CC=CC=C34)C5=C(C)C=CC(Cl)=C5
InChI
InChIKey=MMNNTJYFHUDSKL-UHFFFAOYSA-N
InChI=1S/C24H19ClN4O4/c1-13-7-9-15(25)12-20(13)29-21(30)16-5-3-4-6-17(16)24(29,32)14-8-10-18-19(11-14)27-22(26-18)28-23(31)33-2/h3-12,32H,1-2H3,(H2,26,27,28,31)
| Molecular Formula | C24H19ClN4O4 |
| Molecular Weight | 462.885 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
BMS-908662 (previously known as XL281) is a small molecule Raf kinase inhibitor that lies immediately downstream of RAS and are key components of the RAS/RAF/MEK/ERK kinase-signaling pathway. Bristol-Myers Squibb has received an exclusive worldwide license to develop and commercialize antineoplastic agent XL281. BMS-908662 participated in phase I development for the treatment of patients with melanoma and in combination with cetuximab for patients with colorectal cancer. However, further, development has been discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. | 2015-04 |
|
| Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. | 2015-01-01 |
|
| Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. | 2014-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01086267
Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:18:17 GMT 2025
by
admin
on
Mon Mar 31 18:18:17 GMT 2025
|
| Record UNII |
DW2NWI3TFN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000174997
Created by
admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
|
PRIMARY | |||
|
DW2NWI3TFN
Created by
admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
|
PRIMARY | |||
|
DB12854
Created by
admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
|
PRIMARY | |||
|
870603-16-0
Created by
admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL3545027
Created by
admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
|
PRIMARY | |||
|
56931136
Created by
admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |